|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||128.15 - 129.45|
|52-week range||121.00 - 148.99|
|Beta (3Y monthly)||0.76|
|PE ratio (TTM)||21.40|
|Earnings date||15 Oct 2019|
|Forward dividend & yield||3.80 (2.95%)|
|1y target est||149.28|
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Drugmakers spent a record amount of money lobbying Congress in the first half of the year, trying to defend against the threat of drug pricing reforms that could hit their bottom line such as a new bill revealed by the Senate finance committee on Tuesday. The industry group Pharmaceutical Research and Manufacturers of America spent $16.1m on lobbying in the first half of this year, up 4 per cent from its previous record of $15.5m in the first half of 2018, according to congressional filings. PhRMA, which did not respond to a request for comment, also broke its record for a full year in 2018, dishing out $27.5m in total.
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
The World Health Organization has declared an international emergency over the Ebola epidemic in the Democratic Republic of Congo, which has killed more than 1,600 people over the past year and shows no sign of declining. Dr Tedros Adhanom Ghebreyesus, WHO director-general, announced that the outbreak was now a “public health emergency of international concern” after a meeting of the UN-affiliated organisation’s emergency committee in Geneva. “We need to work together in solidarity with the DRC to end this outbreak,” said Dr Tedros.
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at firstname.lastname@example.orgTo contact the editor responsible for this story: Drew Armstrong at email@example.comFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.